泰国HIV感染者NAT2多态性与抗结核药物肝毒性的药物遗传学-药代动力学队列研究
该前瞻性队列研究纳入894例接受含异烟肼方案预防或治疗结核的泰国HIV感染者,按NAT2基因型分为慢、中间和快乙酰化者。结果显示慢乙酰化者肝毒性风险显著高于快乙酰化者(aOR 2.43;95%CI 1.32-4.48),且NAT2*6A/*6A和*7B/*7B基因型风险增加,*4/*4具保护作用;药代动力学亚组显示慢乙酰化者异烟肼暴露约增加2倍。
要点
- NAT2慢乙酰化者肝毒性风险显著高于快乙酰化者(aOR 2.43;95%CI 1.32-4.48)。
- NAT2*6A/*6A和*7B/*7B基因型与肝毒性风险增加相关,*4/*4具保护作用。
- 慢乙酰化者异烟肼暴露约增加2倍,NAT2指导给药或可提高含异烟肼方案安全性。
核心结论
- NAT2慢乙酰化表型,特别是*6A/*6A和*7B/*7B基因型,与泰国HIV感染者抗结核药物肝毒性风险增加及异烟肼暴露升高相关。
- 纳入NAT2指导的给药可能提高HIV感染者含异烟肼方案的安全性。
研究设计与样本
- 前瞻性队列研究,纳入894例接受含异烟肼方案预防或治疗结核的泰国HIV感染者,按NAT2基因型分为慢、中间和快乙酰化者。
- 药代动力学亚组研究纳入93例,评估不同表型的异烟肼暴露。
主要发现
- 894例中慢乙酰化者占32.4%,中间乙酰化者占41.2%,快乙酰化者占26.4%。
- 肝毒性总体发生率为10.9%,慢乙酰化者最高(15.2%)。
- 慢乙酰化者肝毒性风险高于快乙酰化者(aOR 2.43;95%CI 1.32-4.48)。
- NAT2*6A/*6A(aOR 1.84)和NAT2*7B/*7B(aOR 4.46)与肝毒性风险增加相关,NAT2*4/*4具保护作用(aOR 0.33)。
- 其他独立危险因素包括高基线ALT、HCV合并感染、2HRZE/4HR方案(对比1HP)和依非韦伦为基础抗病毒治疗(对比多替拉韦)。
关键数值与推荐
- 肝毒性定义为转氨酶升高超过正常上限(ULN)的2.5倍。
临床怎么用
- 对接受含异烟肼方案的HIV感染者,可考虑NAT2基因分型以识别肝毒性高风险者。
- 慢乙酰化者尤其是*6A/*6A和*7B/*7B基因型者应加强肝毒性监测。
- NAT2指导的剂量调整可能提高含异烟肼方案的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The N-Acetyltransferase (NAT2) slow acetylator phenotype has been associated with a higher risk of isoniazid (INH)-induced hepatotoxicity. We investigated the association between NAT2 genotypes with inferred acetylator status, hepatotoxicity, and INH pharmacokinetics in Thai people living with HIV (PLWH) receiving INH-based Tuberculosis (TB) preventive or treatment regimens. METHODS: In this prospective cohort study of Thai PLWH initiating INH-based regimens; NAT2 genotyping classified participants as slow (SA), intermediate (IA), or rapid acetylators (RA). Hepatotoxicity was defined as transaminase elevations more than 2.5 times the upper limit of normal (ULN). Multivariable logistic regression identified genotypes and factors associated with hepatotoxicity. A pharmacokinetic (PK) substudy assessed INH exposure across phenotypes. RESULTS: Of 894 participants, 32.4% were SA, 41.2% IA, and 26.4% RA. Hepatotoxicity occurred in 10.9% overall and was highest in SA (15.2%). SA had increased hepatotoxicity risk versus RA (adjusted odds ratio [aOR] 2.43; 95% CI: 1.32-4.48). Genotypes NAT2*6A/*6A (aOR 1.84) and NAT2*7B/*7B (aOR 4.46) were associated with increased risk; NAT2*4/*4 was protective (aOR 0.33). Other independent risk factors included high baseline alanine aminotransferase (ALT), HCV co-infection, 2HRZE/4HR regimen (vs 1HP), and efavirenz-based antiviral therapy (vs dolutegravir). In the PK substudy (n = 93), INH exposure assessed by the area under the concentration time curve from 0 to 24 h, was significantly increased by approximately 2-fold in SA, regardless of anti-TB regimen. CONCLUSIONS: NAT2 SA phenotype, particularly *6A/*6A and *7B/*7B genotypes, is associated with an increased risk of anti-tuberculosis-induced hepatotoxicity and higher INH exposure in Thai PLWH. Incorporating NAT2-guided dosing may enhance safety of INH-containing regimens in PLWH.
引用
- Hiranburana N, Sophonphan J, Kerr SJ, et al. NAT2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic-Pharmacokinetic Cohort Study. J Infect Dis. 2026. PMID: 41037485. doi:10.1093/infdis/jiaf511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。